Cargando…

Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study

Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values < 10.5 g/dL or increase in <1 g/dL) or % transferrin sat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosati, Alberto, Conti, Paolo, Berto, Patrizia, Molinaro, Sabrina, Baldini, Federica, Egan, Colin Gerard, Panichi, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506237/
https://www.ncbi.nlm.nih.gov/pubmed/36142929
http://dx.doi.org/10.3390/jcm11185284
_version_ 1784796673164181504
author Rosati, Alberto
Conti, Paolo
Berto, Patrizia
Molinaro, Sabrina
Baldini, Federica
Egan, Colin Gerard
Panichi, Vincenzo
author_facet Rosati, Alberto
Conti, Paolo
Berto, Patrizia
Molinaro, Sabrina
Baldini, Federica
Egan, Colin Gerard
Panichi, Vincenzo
author_sort Rosati, Alberto
collection PubMed
description Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values < 10.5 g/dL or increase in <1 g/dL) or % transferrin saturation; TSAT of <20%) in the previous 6 months were switched to i.v. ferric carboxymaltose (FCM). Changes in iron status parameters, economic and safety measures were also assessed. Seventy-seven hemodialysis patients aged 68 ± 15 years were included. Erythropoietin resistance index decreased from 24.2 ± 14.6 at pre-switch to 20.4 ± 14.6 after 6 months of FCM treatment and Hb levels ≥10.5 g/dL improved from 61% to 75.3% patients (p = 0.042). A 1 g/dL increase in Hb levels was also seen in 26% of patients as well as a 37.7% increase in patients achieving >20% increase in TSAT after FCM. Levels of Hb, TSAT and ferritin parameters increased during FCM treatment with a concomitant decrease in ESA. A mixed-model analysis, which also considered gender, confirmed these trends. Safety variables remained stable, no hypersensitivity reaction was recorded and only one patient reported an adverse event after FCM. FCM treatment was associated with a cost saving of 11.11 EUR/patient/month. These results confirm the efficacy, safety and cost-effectiveness of FCM in correcting IDA in hemodialysis patients.
format Online
Article
Text
id pubmed-9506237
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95062372022-09-24 Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study Rosati, Alberto Conti, Paolo Berto, Patrizia Molinaro, Sabrina Baldini, Federica Egan, Colin Gerard Panichi, Vincenzo J Clin Med Article Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values < 10.5 g/dL or increase in <1 g/dL) or % transferrin saturation; TSAT of <20%) in the previous 6 months were switched to i.v. ferric carboxymaltose (FCM). Changes in iron status parameters, economic and safety measures were also assessed. Seventy-seven hemodialysis patients aged 68 ± 15 years were included. Erythropoietin resistance index decreased from 24.2 ± 14.6 at pre-switch to 20.4 ± 14.6 after 6 months of FCM treatment and Hb levels ≥10.5 g/dL improved from 61% to 75.3% patients (p = 0.042). A 1 g/dL increase in Hb levels was also seen in 26% of patients as well as a 37.7% increase in patients achieving >20% increase in TSAT after FCM. Levels of Hb, TSAT and ferritin parameters increased during FCM treatment with a concomitant decrease in ESA. A mixed-model analysis, which also considered gender, confirmed these trends. Safety variables remained stable, no hypersensitivity reaction was recorded and only one patient reported an adverse event after FCM. FCM treatment was associated with a cost saving of 11.11 EUR/patient/month. These results confirm the efficacy, safety and cost-effectiveness of FCM in correcting IDA in hemodialysis patients. MDPI 2022-09-07 /pmc/articles/PMC9506237/ /pubmed/36142929 http://dx.doi.org/10.3390/jcm11185284 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rosati, Alberto
Conti, Paolo
Berto, Patrizia
Molinaro, Sabrina
Baldini, Federica
Egan, Colin Gerard
Panichi, Vincenzo
Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
title Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
title_full Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
title_fullStr Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
title_full_unstemmed Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
title_short Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
title_sort efficacy, safety and pharmacoeconomic analysis of intravenous ferric carboxymaltose in anemic hemodialysis patients unresponsive to ferric gluconate treatment: a multicenter retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506237/
https://www.ncbi.nlm.nih.gov/pubmed/36142929
http://dx.doi.org/10.3390/jcm11185284
work_keys_str_mv AT rosatialberto efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy
AT contipaolo efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy
AT bertopatrizia efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy
AT molinarosabrina efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy
AT baldinifederica efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy
AT egancolingerard efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy
AT panichivincenzo efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy